IMMNOV Stock Overview
A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.45 |
| 52 Week High | kr4.73 |
| 52 Week Low | kr0.51 |
| Beta | 2.6 |
| 1 Month Change | -16.26% |
| 3 Month Change | 16.16% |
| 1 Year Change | -33.85% |
| 3 Year Change | -98.58% |
| 5 Year Change | -99.14% |
| Change since IPO | -95.11% |
Recent News & Updates
Recent updates
Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation
Apr 20
We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate
Dec 09Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?
May 13Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Jan 18We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth
Aug 28What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?
Mar 09Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Feb 03
Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 30Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares
Dec 03Shareholder Returns
| IMMNOV | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.5% | -4.2% | 0.1% |
| 1Y | -33.8% | -9.7% | 14.2% |
Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: IMMNOV underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| IMMNOV volatility | |
|---|---|
| IMMNOV Average Weekly Movement | 26.7% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IMMNOV's share price has been volatile over the past 3 months.
Volatility Over Time: IMMNOV's weekly volatility has decreased from 38% to 27% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| IMMNOV fundamental statistics | |
|---|---|
| Market cap | kr65.76m |
| Earnings (TTM) | -kr260.73m |
| Revenue (TTM) | kr1.21m |
54.3x
P/S Ratio-0.3x
P/E RatioIs IMMNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOV income statement (TTM) | |
|---|---|
| Revenue | kr1.21m |
| Cost of Revenue | kr5.64m |
| Gross Profit | -kr4.43m |
| Other Expenses | kr256.30m |
| Earnings | -kr260.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -5.76 |
| Gross Margin | -365.98% |
| Net Profit Margin | -21,529.89% |
| Debt/Equity Ratio | 0% |
How did IMMNOV perform over the long term?
See historical performance and comparison